- News & Events
- Contact Us
|View printer-friendly version|
|Amgen to Acquire Filgrastim and Pegfilgrastim in Europe from Roche|
|THOUSAND OAKS, CA, USA and BASEL, SWITZERLAND - May 7, 2002 - Roche and Amgen
(NASDAQ:AMGN), announced today that Amgen has purchased from Roche the assets
and business related to filgrastim and pegfilgrastim in the European Union, Switzerland
Filgrastim and pegfilgrastim are white-cell boosting therapeutics that are used to decrease the incidence of neutropenia, which can lead to patients contracting potentially life threatening infections following chemotherapy. Filgrastim has been commercialized by Amgen and Roche under the Neupogen(R) and Granulokine(R) trade names. Amgen also currently markets in the U.S. pegfilgrastim, as NeulastaTM, a long-acting version of filgrastim.
In December 2001 Roche announced the planned merger of its Japanese subsidiary with the Japanese company Chugai. As a result of this merger, Roche is selling part of its European filgrastim and pegfilgrastim business to Amgen, as Chugai commercializes a competitive drug.
Amgen will pay Roche $137.5 million for this acquisition. Roche will continue as the licensee for filgrastim and pegfilgrastim in certain countries in Eastern Europe, the Middle East, Africa, Asia and Latin America.
About Filgrastim and Pegfilgrastim
Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. In addition, sales of our products are affected by reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers. These government regulations and reimbursement policies may affect the development, usage and pricing of our products.
In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.
Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Amgen. Amgen is providing this information as of May 7, 2002 and expressly disclaims any duty to update information contained in this press release.
# # #
CONTACT: Amgen, Thousand Oaks